Mikulski, D.; Robak, P.; Ryżewska, W.; Stańczak, K.; Kościelny, K.; Góra-Tybor, J.; Robak, T.
Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. J. Clin. Med. 2022, 11, 5908.
https://doi.org/10.3390/jcm11195908
AMA Style
Mikulski D, Robak P, Ryżewska W, Stańczak K, Kościelny K, Góra-Tybor J, Robak T.
Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. Journal of Clinical Medicine. 2022; 11(19):5908.
https://doi.org/10.3390/jcm11195908
Chicago/Turabian Style
Mikulski, Damian, Paweł Robak, Wiktoria Ryżewska, Kamila Stańczak, Kacper Kościelny, Joanna Góra-Tybor, and Tadeusz Robak.
2022. "Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study" Journal of Clinical Medicine 11, no. 19: 5908.
https://doi.org/10.3390/jcm11195908
APA Style
Mikulski, D., Robak, P., Ryżewska, W., Stańczak, K., Kościelny, K., Góra-Tybor, J., & Robak, T.
(2022). Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. Journal of Clinical Medicine, 11(19), 5908.
https://doi.org/10.3390/jcm11195908